MicroPort CardioFlow Medtech Corporation Stock

Equities

2160

KYG6082P1054

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 am EDT 5-day change 1st Jan Change
1.03 HKD +5.10% Intraday chart for MicroPort CardioFlow Medtech Corporation +11.96% -36.42%

Financials

Sales 2023 336M 46.4M 363M Sales 2024 * 449M 61.9M 485M Capitalization 2.3B 317M 2.49B
Net income 2023 -472M -65.14M -510M Net income 2024 * -169M -23.32M -183M EV / Sales 2023 10.6 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 5.13 x
P/E ratio 2023
-7.36 x
P/E ratio 2024 *
-13.4 x
Employees 592
Yield 2023 *
-
Yield 2024 *
-
Free-Float 41.41%
More Fundamentals * Assessed data
Dynamic Chart
Microport Cardioflow Inks Services Deal with Subsidiary MT
MicroPort CardioFlow Medtech Corporation Enters into the 2024 MP CardioAdvent Service Procurement Framework Agreement CI
MicroPort CardioFlow Medtech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MicroPort CardioFlow Medtech Corporation Provides Consolidated Revenue Guidance for the Year Ended December 31, 2023 CI
China Approves MicroPort CardioFlow's Application for Atrial Appendage Closure System; Shares Fall 3% MT
Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System CI
MicroPort CardioFlow Subsidiary to Buy 51% Stake in Medical Device Maker MT
MicroPort CardioFlow Medtech to Renew Four Agreements With Parent MT
MicroPort's Transcatheter Aortic Heart-Valve Implantation Product Completes Seven Trials in Europe MT
MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe CI
MicroPort CardioFlow's Transcatheter Aortic Heart Valve Implantation Device Enters Clinical Application Phase MT
MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product CI
Transcript : MicroPort CardioFlow Medtech Corporation, H1 2023 Earnings Call, Aug 31, 2023
MicroPort CardioFlow Medtech Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
MicroPort Cardioflow Medtech Corporation Announces Executive Changes CI
More news

Latest transcript on MicroPort CardioFlow Medtech Corporation

1 day+5.10%
1 week+11.96%
Current month-8.85%
1 month-2.83%
3 months-20.16%
6 months-39.77%
Current year-36.42%
More quotes
1 week
0.92
Extreme 0.92
1.03
1 month
0.85
Extreme 0.85
1.13
Current year
0.85
Extreme 0.85
1.63
1 year
0.85
Extreme 0.85
2.49
3 years
0.85
Extreme 0.85
18.30
5 years
0.85
Extreme 0.85
22.20
10 years
0.85
Extreme 0.85
22.20
More quotes
Managers TitleAgeSince
President 58 21-12-31
Chairman 39 16-08-31
Director/Board Member 45 05-12-31
Members of the board TitleAgeSince
Director/Board Member 60 21-01-14
Director/Board Member 47 19-08-04
Chairman 39 16-08-31
More insiders
Date Price Change Volume
24-04-26 1.03 +5.10% 6,238,001
24-04-25 0.98 0.00% 3,902,000
24-04-24 0.98 +1.03% 2,676,005
24-04-23 0.97 +4.30% 4,846,117
24-04-22 0.93 +1.09% 3,569,016

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT

More quotes
Microport Cardioflow Medtech Corp is a China-based investment holding company mainly engaged in the medical device industry. The Company is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The Company's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The Company mainly conducts business within the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9534 CNY
Average target price
2.412 CNY
Spread / Average Target
+153.01%
Consensus

Annual profits - Rate of surprise